Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Inventory (2024 - 2025)

Syndax Pharmaceuticals has reported Change in Inventory over the past 2 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Change in Inventory at $7.8 million for Q4 2025, up 2031.42% from a year ago — trailing twelve months through Dec 2025 was $32.1 million (up 8668.03% YoY), and the annual figure for FY2025 was $32.1 million, up 8668.03%.
  • Change in Inventory for Q4 2025 was $7.8 million at Syndax Pharmaceuticals, up from $7.2 million in the prior quarter.
  • Over the last five years, Change in Inventory for SNDX hit a ceiling of $12.9 million in Q2 2025 and a floor of $366000.0 in Q4 2024.